Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
2017 ◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. 506-506
◽
Keyword(s):
Keyword(s):
2018 ◽
Vol 24
(21)
◽
pp. 5292-5304
◽
2015 ◽
Keyword(s):